Inactivated Vaccine-Induced SARS-CoV-2 Variant-SpecificImmunity in Children

Vista sencilla de ítem
dc.contributor.authorJorge A. Soto
dc.contributor.authorFelipe Melo González
dc.contributor.authorCristián Gutierrez Vera
dc.contributor.authorBárbara M. Schultz
dc.contributor.authorRoslye V. Berríos Rojas
dc.contributor.authorDaniela Rivera Pérez
dc.contributor.authorAlejandro Piña Iturbe
dc.contributor.authorGuillermo Hoppe Elsholz
dc.contributor.authorLuisa F. Duarte
dc.contributor.authorYaneisi Vázquez
dc.contributor.authorDaniela Moreno Tapia
dc.contributor.authorMariana Ríos
dc.contributor.authorPablo A. Palacios
dc.contributor.authorRichard Garcia Betancourt
dc.contributor.authorÁlvaro Santibañez
dc.contributor.authorGaspar A. Pacheco
dc.contributor.authorConstanza Mendez
dc.contributor.authorCatalina A. Andrade
dc.contributor.authorPedro H. Silva
dc.contributor.authorBenjamín Diethelm Varela
dc.contributor.authorPatricia Astudillo
dc.contributor.authorMario Calvo
dc.contributor.authorAntonio Cárdenas
dc.contributor.authorMarcela González
dc.contributor.authorMacarena Goldsack
dc.contributor.authorValentina Gutiérrez
dc.contributor.authorMarcela Potin
dc.contributor.authorAndrea Schilling
dc.contributor.authorLorena I. Tapia
dc.contributor.authorLoreto Twele
dc.contributor.authorRodolfo Villena
dc.contributor.authorAlba Grifoni
dc.contributor.authorAlessandro Sette
dc.contributor.authorDaniela Weiskopf
dc.contributor.authorRodrigo A. Fasce
dc.contributor.authorJorge Fernández
dc.contributor.authorJudith Mora
dc.contributor.authorEugenio Ramírez
dc.contributor.authorAracelly Gaete Argel
dc.contributor.authorMónica L. Acevedo
dc.contributor.authorFernando Valiente Echeverría
dc.contributor.authorRicardo Soto Rifo
dc.contributor.authorAngello Retamal Díaz
dc.contributor.authorNathalia Muñoz Jofré
dc.contributor.authorPedCoronaVac03CL Study Group
dc.contributor.authorXing Meng
dc.contributor.authorQianqian Xin
dc.contributor.authorEduardo Alarcón Bustamante
dc.contributor.authorJosé V. González Aramundiz
dc.contributor.authorNicole Le Corre
dc.contributor.authorMaría Javiera Álvarez Figueroa
dc.contributor.authorPablo A. González
dc.contributor.authorKatia Abarca
dc.contributor.authorCecilia Perret
dc.contributor.authorLeandro J. Carreño
dc.contributor.authorSusan M. Bueno
dc.contributor.authorAlexis M. Kalergis
dc.date.accessioned2025-12-16T12:53:01Z
dc.date.available2025-12-16T12:53:01Z
dc.date.issued2022
dc.description.abstractMultiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been evaluated in clinical trials. However, trials addressing the immune response in the pediatric population are scarce. The inactivated vaccine CoronaVac has been shown to be safe and immunogenic in a phase 1/2 clinical trial in a pediatric cohort in China. Here, we report interim safety and immunogenicity results of a phase 3 clinical trial for CoronaVac in healthy children and adolescents in Chile. Participants 3 to 17 years old received two doses of CoronaVac in a 4-week interval until 31 December 2021. Local and systemic adverse reactions were registered for volunteers who received one or two doses of CoronaVac. Whole-blood samples were collected from a subgroup of 148 participants for humoral and cellular immunity analyses. The main adverse reaction reported after the first and second doses was pain at the injection site. Four weeks after the second dose, an increase in neutralizing antibody titer was observed in subjects relative to their baseline visit. Similar results were found for activation of specific CD41 T cells. Neutralizing antibodies were identified against the Delta and Omicron variants. However, these titers were lower than those for the D614G strain. Importantly, comparable CD41 T cell responses were detected against these variants of concern. Therefore, CoronaVac is safe and immunogenic in subjects 3 to 17 years old, inducing neutralizing antibody secretion and activating CD41 T cells against SARS-CoV-2 and its variants. (This study has been registered at ClinicalTrials .gov under no. NCT04992260.)
dc.description.sponsorship1. Sinovac Biotech 2. FONDECYT 1190156, Agencia Nacional de Investigación y Desarrollo (ANID). 3. FONDECYT 1211547, Agencia Nacional de Investigación y Desarrollo (ANID). 4. FONDECYT 1190830, Agencia Nacional de Investigación y Desarrollo (ANID). 5. El Instituto Milenio de Inmunología e Inmunoterapia, Programa ICN09_016 (anteriormente P09/016-F) de la ANID-Iniciativa Científica Milenio. 6. El Fondo de Innovación para la Competitividad FIC-R 2017 (código BIP 30488811-0). 7. Instituto Nacional de Alergias y Enfermedades Infecciosas, Institutos Nacionales de Salud, Departamento de Salud y Servicios Humanos, bajo el contrato n.° 75N93021C00016 a A.S. y el contrato n.° 75N93019C00065.
dc.identifier.doi10.1128/mbio.01311-22
dc.identifier.issn21612129
dc.identifier.urihttps://repositorioabierto.uantof.cl/handle/uantof/584
dc.language.isoen
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourcemBio
dc.titleInactivated Vaccine-Induced SARS-CoV-2 Variant-SpecificImmunity in Children
dc.typeArticle
oaire.citation.volume13
organization.identifier.rorUniversidad de Antofagasta
uantof.identificator.departmentDepartamento Ciencias Médicas
uantof.identificator.facultyFacultad de Medicina y Odontología
uantof.identificator.facultyFacultad de Ciencias del Mar y Recursos Biológicos
uantof.identificator.facultyFacultad de Ciencias de la Salud
Archivos
Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
soto-et-al-2022-inactivated-vaccine-induced-sars-cov-2-variant-specific-immunity-in-children.pdf
Tamaño:
2.37 MB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descripción:
Descargar
Colecciones
Departamento de Ciencias médicas
Departamento de Biotecnología
Departamento de Tecnología médica